2024-11-22 05:00:00
France has more than 8 million people suffering from obesity. In this context, the arrival on the market of anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you had difficulty losing weight, your options were very limited. These medications are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and emphasize the lack of perspective on their long-term effects.
In this video, we return to the active ingredient of these new drugs, which imitate a digestive hormone naturally produced by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to be eligible for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To find out more about these new treatments and the excitement they are causing in the financial markets, you will find a complete breakdown below.
Read later
“Understand in three minutes”
The explanatory videos that make up the “Understand in three minutes” series are produced by the Vertical Videos department of the Monde. Broadcast primarily on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to put major events into context in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
1732259309
#antiobesity #drugs #Wegogy #Mounjaro #work #Understand #minutes
How do current obesity treatments, including medications and lifestyle changes, compare in terms of effectiveness and patient outcomes?
**Interview: Exploring New Hope in Obesity Treatments**
*Date: November 22, 2024*
*Interviewer: [Your Name]*
*Guest: Dr. Claire Moreau, Specialist in Obesity Medicine*
**[Your Name]:** Good morning, Dr. Moreau. Thank you for joining us today to discuss the recent developments in obesity treatments, particularly Wegovy and Mounjaro. With over 8 million people in France suffering from obesity, how significant do you believe these new medications are for patients?
**Dr. Claire Moreau:** Good morning! The arrival of Wegovy and Mounjaro on the market is indeed a significant advancement in obesity management. For many patients, traditional weight loss methods have proven inadequate, and this has left them feeling frustrated. These new medications offer a glimmer of hope, especially for individuals who have struggled with obesity for years. They work by mimicking a naturally occurring hormone, glucagon-like peptide-1 (GLP-1), which helps regulate appetite and insulin levels.
**[Your Name]:** That sounds promising. However, I understand there are mixed opinions among health professionals regarding these treatments. Can you elaborate on the concerns some specialists have raised?
**Dr. Claire Moreau:** Absolutely. While many obesity specialists are optimistic about the effectiveness of these medications, others express caution. One major concern is the unknown long-term effects of using these drugs. Since they are relatively new to the market, we don’t yet have extensive data on how they might affect patients over several years. Furthermore, there are also questions about potential side effects and their impact on different populations.
**[Your Name]:** Considering the effectiveness of Wegovy and Mounjaro, what would you recommend for patients who are trying to decide whether to start these medications?
**Dr. Claire Moreau:** I always encourage patients to have open discussions with their healthcare providers. It’s crucial for individuals to consider their personal health history, the presence of any co-existing conditions, and their weight loss goals. These medications may not be suitable for everyone, and behavioral interventions, such as diet and exercise programs, should also be part of a comprehensive weight management plan.
**[Your Name]:** Before we conclude, is there anything else you would like to share about the future of obesity treatments?
**Dr. Claire Moreau:** I believe we are on the brink of an exciting era in obesity management. With ongoing research and potential new treatments on the horizon, patients may soon have even more options. It’s important for us, as healthcare providers, to stay informed and guide our patients wisely. Weight management is a holistic process, and together, we can find the best path forward for each individual.
**[Your Name]:** Thank you, Dr. Moreau, for your insights today. It’s clear that while there is hope with these new medications, a careful and well-rounded approach remains essential in combating obesity.
*End of Interview*